Investigation of chemotherapy-induced cardiac dysfunction in breast cancer.

IF 1.8 4区医学 Q3 INFECTIOUS DISEASES Journal of Chemotherapy Pub Date : 2025-02-20 DOI:10.1080/1120009X.2025.2466278

Sai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, Ansari Maha Faisal, Vishva Maheshbhai Patel, Ewuradjoa Ayirebi-Acquah, Venkata Sai Harsha Bhargav Chenna, Hend Makky, Misbah Kamal Khan, Rohan Raj, Jubran Al Hooti, Sofia Alik, Parvinder Kaur, Keti Solomnishvili, Shree Rath

{"title":"Investigation of chemotherapy-induced cardiac dysfunction in breast cancer.","authors":"Sai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, Ansari Maha Faisal, Vishva Maheshbhai Patel, Ewuradjoa Ayirebi-Acquah, Venkata Sai Harsha Bhargav Chenna, Hend Makky, Misbah Kamal Khan, Rohan Raj, Jubran Al Hooti, Sofia Alik, Parvinder Kaur, Keti Solomnishvili, Shree Rath","doi":"10.1080/1120009X.2025.2466278","DOIUrl":null,"url":null,"abstract":"<p><p>Although recent advancements in cancer treatment have significantly improved survival rates, they have also raised concerns regarding severe adverse effects, including cardiotoxicity. We conducted a prospective study at Dayanand Medical College and Hospital, Ludhiana to assess chemotherapy-related cardiac dysfunction in newly diagnosed, histologically confirmed breast cancer cases. Among 97 breast cancer patients undergoing chemotherapy, 13 (13.4%) developed left ventricular dysfunction (LVD), predominantly in younger patients with left-sided breast involvement (64.9%). A significant association was found between estrogen receptor (ER) positivity and LVD risk (P = 0.03), with 15.4% of LVD patients also being hypertensive. The incidence of LVD was notably high at 38.5% among patients receiving trastuzumab, while cumulative doses of doxorubicin and cyclophosphamide did not show significant correlation with LVD. Recovery was promising, with 76.9% of affected patients demonstrating significant improvement post-treatment. These findings highlight the need for continuous cardiac monitoring and personalized treatment strategies to mitigate LVD risk.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2466278","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Although recent advancements in cancer treatment have significantly improved survival rates, they have also raised concerns regarding severe adverse effects, including cardiotoxicity. We conducted a prospective study at Dayanand Medical College and Hospital, Ludhiana to assess chemotherapy-related cardiac dysfunction in newly diagnosed, histologically confirmed breast cancer cases. Among 97 breast cancer patients undergoing chemotherapy, 13 (13.4%) developed left ventricular dysfunction (LVD), predominantly in younger patients with left-sided breast involvement (64.9%). A significant association was found between estrogen receptor (ER) positivity and LVD risk (P = 0.03), with 15.4% of LVD patients also being hypertensive. The incidence of LVD was notably high at 38.5% among patients receiving trastuzumab, while cumulative doses of doxorubicin and cyclophosphamide did not show significant correlation with LVD. Recovery was promising, with 76.9% of affected patients demonstrating significant improvement post-treatment. These findings highlight the need for continuous cardiac monitoring and personalized treatment strategies to mitigate LVD risk.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌化疗诱发心功能障碍的研究。

尽管癌症治疗的最新进展显著提高了生存率，但也引起了对严重副作用的担忧，包括心脏毒性。我们在Ludhiana Dayanand医学院和医院进行了一项前瞻性研究，以评估新诊断的组织学证实的乳腺癌患者化疗相关心功能障碍。在97例接受化疗的乳腺癌患者中，13例（13.4%）发生左心室功能障碍（LVD），主要发生在年轻的左侧乳房受损伤患者中（64.9%）。雌激素受体（ER）阳性与LVD风险显著相关（P = 0.03）， 15.4%的LVD患者同时患有高血压。在接受曲妥珠单抗治疗的患者中，LVD的发生率高达38.5%，而阿霉素和环磷酰胺的累积剂量与LVD没有显着相关性。康复是有希望的，76.9%的患者在治疗后表现出显著的改善。这些发现强调了持续心脏监测和个性化治疗策略以降低LVD风险的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.